Fig. 4From: Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension studyAdjusted mean number of new/newly enlarging T2 hyperintense lesions. Results from the SELECT placebo group have been published previously [3]. The adjusted mean number of T2 hyperintense lesions was estimated from a negative binomial regression adjusted for baseline number of T2 hyperintense lesions. *Gold et al. [3]Back to article page